Healthcare Services company Vimta Labs announced H1FY25 & Q2FY25 results Q2FY25 Financial Highlights: Total Income for Q2FY25 was at Rs 854 million. EBITDA for Q2FY25 was Rs 306 million; EBITDA margin was at 35.8%. PBT for Q2FY25 was at Rs 219 million. Q2FY25 PAT was at Rs 170 million; PAT margin was at 19.9%. Basic EPS in Q2FY25 was Rs 7.7. H1FY25 Financial Highlights: Total Income for H1FY25 was at Rs 1,610 million. EBITDA for H1FY25 was Rs 572 million; EBITDA margin was at 35.5%. PBT for H1FY25 was at Rs 401 million. H1FY25 PAT was at Rs 309 million; PAT margin was at 19.2%. Basic EPS in H1FY25 was Rs 13.9. Total Debt as of 30th September 2024 stood at Rs 116 million. Cash and Cash equivalents including bank balance stood at Rs 278 million as of 30th September 2024. Harita Vasireddi, Managing Director, Vimta Labs, said: "We are pleased to report a strong operational performance for Q2FY25, with revenues of Rs 854 million, reflecting a 26.4% YoY growth. Our EBITDA rose by 57.3% YoY, and net profit surged by 109.9%. This performance was primarily driven by our pharmaceutical services, which continue to lead the business. As stated in our August 30, 2024, press release, Vimta Labs has divested the Diagnostic and Pathological services business to Thyrocare Technologies. This decision allows us to sharpen our focus on core services and optimize resources for sustained growth, resulting in a significant improvement in our EBITDA margins, which now exceed 35%, up from the previous range of 23% to 30%. Looking ahead, our Pharmaceutical services continue to show promising growth, and we anticipate that our food testing services will also contribute to growth in coming quarteRs We are also expanding our electrical and electronics testing capabilities and preparing to commission a new facility in couple of quarteRs We remain committed to driving sustainable and impactful growth for our investors.” Result PDF